Welcome to our dedicated page for QIAGEN N.V. news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on QIAGEN N.V. stock.
QIAGEN N.V. (symbol: QGEN) is a leading global provider of sample-to-insight solutions that transform biological materials into valuable molecular insights. The company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Its assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases from QIAGEN interpret data to report relevant, actionable insights. Automation solutions tie these components together in seamless and cost-effective molecular testing workflows.
QIAGEN serves a diverse customer base of over 500,000 worldwide in sectors such as molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharmaceutical and biotechnology companies), and academia (life sciences research). As of June 30, 2015, the company employed approximately 4,400 people across 35 locations globally. Additional information can be found on their website at http://www.qiagen.com.
QIAGEN's proprietary sample and assay technology enables the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company's revenue is almost evenly split between life sciences and molecular diagnostics applications, with nearly 90% of its revenue derived from consumables and the remaining from instrumentation and related services. The largest portion of QIAGEN's revenue comes from the Americas (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Recent achievements include:
- Q1 2024 net sales of $459 million (-5% at actual rates, -5% at constant exchange rates, CER), with a diluted EPS of $0.36 and an adjusted diluted EPS of $0.46. The net sales at CER of $462 million were ahead of the outlook for at least $455 million CER, and the adjusted diluted EPS of $0.47 CER was ahead of the $0.44 CER outlook.
- Strong operating cash flow rose by 85% to $133 million versus Q1 2023.
- The QCI Secondary Analysis software, integrated with QCI Interpret, facilitates high-throughput secondary analysis of clinical next-generation sequencing data.
- Collaborations aimed at creating novel digital PCR assays to improve DNA analysis in forensics and human identification.
- Introduction of the QIAstat-Dx Respiratory Panel Plus for accurate diagnosis of respiratory infections, capable of generating results in about one hour with minimal hands-on time.
- Enhancements to the QIAGEN Clinical Insight Interpret platform, which has processed over 4 million NGS patient test cases for oncology and hereditary diseases worldwide.
- New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis, complementing the company's existing assay offerings.
QIAGEN continues to innovate and maintain its leading position in the molecular diagnostics and life sciences industries. The company's ongoing efforts to expand its product offerings and enhance its technologies ensure that it remains a trusted partner for researchers and healthcare providers worldwide.
QIAGEN has signed a collaboration agreement with Neuron23 to develop a companion diagnostic for a LRRK2 inhibitor aimed at treating Parkinson’s disease. This assay will utilize next-generation sequencing (NGS) technology to identify biomarkers predicting patient responsiveness. The collaboration enhances QIAGEN's NGS testing portfolio, expanding its precision medicine applications into neurology. Neuron23's LRRK2 inhibitor is in late-stage preclinical development, and this partnership is part of QIAGEN's strategy to leverage its expertise in molecular testing to support groundbreaking therapies.
Neuron23 and QIAGEN announced a collaboration on September 14, 2022, to develop the first companion diagnostic for Neuron23’s LRRK2 inhibitor aimed at treating Parkinson’s disease. Under the agreement, QIAGEN will create a clinical trial assay detecting biomarkers that predict patient responsiveness to the drug. This assay will be integrated into a next-generation sequencing workflow, facilitating concurrent submissions for FDA approval of both the diagnostic test and drug application.
The collaboration highlights the potential of precision medicine in neurodegenerative diseases.
QIAGEN has launched the QIAstat-Dx Viral Vesicular Panel RUO, a groundbreaking test to differentiate monkeypox from five other pathogens. This test, utilizing gold-standard PCR technology, is vital for global surveillance as monkeypox cases increase. Currently available for research use only, the panel will support healthcare authorities in the fight against infectious diseases. With over 3,000 QIAstat-Dx devices deployed worldwide, QIAGEN aims to enhance testing capabilities significantly as they prepare for potential clinical applications pending regulatory developments.
QIAGEN (NYSE: QGEN) has announced significant enhancements to its QIAcuity digital PCR (dPCR) systems, including 13 new kits and assays for AAV viral titer and host cell DNA quantification, aimed specifically at biopharma applications. With over 1,000 cumulative placements since launch in late 2020, the updates also feature an upgraded software suite for GMP compliance. These developments are designed to improve efficiency and expand the utility of QIAcuity for biopharma customers, enhancing drug development processes.
QIAGEN N.V. reported Q2 2022 net sales of
QIAGEN's Clinical Insights (QCI) platform has surpassed three million analyzed cases, reflecting a remarkable annual growth rate of over 35%, equivalent to 700,000 new cases. This software has outperformed competitors, analyzing five times more cases than other offerings. QCI integrates advanced Augmented Molecular Intelligence, enabling healthcare providers to enhance NGS testing reliability. QIAGEN aims to continue expanding its comprehensive solutions to meet the growing demand in the genetic analysis sector.
QIAGEN N.V. (NYSE: QGEN) will release its second quarter 2022 results on Wednesday, July 27, after 22:05 Frankfurt time. A conference call is scheduled for Thursday, July 28, at 15:30 Frankfurt time. Participants can join the call via callback connection, phone, or audio webcast. The company provides innovative solutions for molecular diagnostics and life sciences, serving over 500,000 customers globally. For further details, visit qiagen.com.
Relation Therapeutics has successfully raised
Dr.
QIAGEN (NYSE: QGEN) receives validation from the CDC for its QIAcuity digital PCR system for wastewater surveillance, marking a shift from traditional qPCR methods. This endorsement allows public health labs to utilize QIAcuity for detecting 30 pathogens, including SARS-CoV-2. Previously, QIAcuity was adopted in public health labs across 70% of U.S. states, enabling rapid results in just two hours. The CDC will now exclusively accept data from QIAcuity and another approved digital PCR platform, reinforcing QIAGEN's role in infectious disease monitoring and expanding its applications beyond COVID-19.
FAQ
What is the current stock price of QIAGEN N.V. (QGEN)?
What is the market cap of QIAGEN N.V. (QGEN)?
What does QIAGEN N.V. do?
How many employees does QIAGEN N.V. have?
What are QIAGEN's recent financial achievements?
What industries does QIAGEN serve?
What are QIAGEN’s proprietary technologies?
Where can I find more information about QIAGEN?
What are some of QIAGEN's recent innovations?
How is QIAGEN's revenue split?
Which regions contribute most to QIAGEN's revenue?
What is the QIAstat-Dx Respiratory Panel Plus?
